Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Programmatic Asset

PROVEN INTELLIGENCE IN RESEARCH VECTOR PRODUCTION.

Programmatic Asset

CELL & GENE | RNA | BIOLOGICS

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Executive Summary

Franklin Biolabs produces high-titer, research-grade lentiviral vectors specifically optimized for the transduction of induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs). We detail our approach to generating VSV-G pseudotyped vectors and advanced surface modifications, such as PEGylation, to enhance vector stability for complex in vivo applications. Our process is designed to support global research programs, with vector characterization data suitable for inclusion in multi-jurisdictional regulatory filings, including those governed by ICH guidelines.

Frequently Asked Questions

What makes lentiviral vectors suitable for transducing stem cells like iPSCs and MSCs?

Lentiviral vectors are highly effective for transducing both dividing and non-dividing cells, including stem cell populations. Their ability to integrate into the host genome facilitates stable, long-term expression of a genetic payload, which is a requirement for creating stable cell lines or for therapeutic applications involving cell differentiation.

How does Franklin Biolabs ensure high-quality lentivirus production for sensitive cell types?

We utilize established protocols for generating high-titer vectors, typically pseudotyped with vesicular stomatitis virus G (VSV-G) protein for broad tropism and stability. Each production lot undergoes rigorous quality control analytics to confirm titer, purity, and identity, ensuring consistent performance for demanding applications like iPSC and MSC transduction.

Can you produce modified lentiviral vectors for improved in vivo performance?

Yes. We can incorporate advanced modifications to enhance vector performance. A key example is PEGylation, which shields the vector from serum inactivation. This modification extends the vector’s circulation half-life, improving transduction efficiency in systemic delivery models, a finding supported by peer-reviewed data (PMID: 14694122).

Lentiviral Vectors for Advanced Stem Cell Engineering

The effective genetic modification of iPSCs and MSCs is foundational for developing next-generation therapies. These applications demand lentiviral vectors with high transduction efficiency, purity, and functional stability to ensure reliable gene expression without compromising cell viability or differentiation potential. Franklin Biolabs produces research-grade lentiviral vectors tailored to meet these exact requirements.

Our production platform focuses on generating VSV-G pseudotyped lentivirus, a robust system that enables efficient entry into a wide range of cell types, including historically difficult-to-transduce stem cell lines. This approach provides the consistency and high titers necessary for both in vitro cell line development and subsequent in vivo evaluation.

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

Enhancing Vector Stability for In Vivo Applications

For therapeutic programs advancing toward in vivo models, standard vector stability can be a limiting factor. We address this by offering advanced vector modifications. Drawing from established research, surface PEGylation of VSV-G pseudotyped lentivirus has been shown to prevent serum inactivation, a significant advantage for systemic delivery protocols. This modification directly translates to improved vector performance and more reliable data from preclinical models.

To support accelerated research programs, our project management and logistics are integrated to provide rapid turnaround. Vector release requests are processed to enable overnight shipment, ensuring materials arrive qualified and ready for immediate use.

Our operations, housed within a >100,000 sq ft facility, are structured to support accelerated research timelines. We provide comprehensive documentation with each vector lot, designed to support global programs and facilitate straightforward inclusion into Investigational Medicinal Product Dossier (IMPD) submissions or other international regulatory filings.

This service is part of our broader vector production capabilities, which you can explore further on our main Research Vector Services page.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities